161 related articles for article (PubMed ID: 18475287)
1. Molecular targeting of Bcl-2 overcomes prostate cancer cell adaptation to XIAP gene downregulation.
Nakano Y; Bilim V; Yuuki K; Muto A; Kato T; Nagaoka A; Tomita Y
Prostate Cancer Prostatic Dis; 2009; 12(1):34-40. PubMed ID: 18475287
[TBL] [Abstract][Full Text] [Related]
2. Antisense RNA down-regulation of bcl-xL Expression in prostate cancer cells leads to diminished rates of cellular proliferation and resistance to cytotoxic chemotherapeutic agents.
Vilenchik M; Raffo AJ; Benimetskaya L; Shames D; Stein CA
Cancer Res; 2002 Apr; 62(7):2175-83. PubMed ID: 11929841
[TBL] [Abstract][Full Text] [Related]
3. XIAP gene downregulation by small interfering RNA inhibits proliferation, induces apoptosis, and reverses the cisplatin resistance of ovarian carcinoma.
Ma JJ; Chen BL; Xin XY
Eur J Obstet Gynecol Reprod Biol; 2009 Oct; 146(2):222-6. PubMed ID: 19758744
[TBL] [Abstract][Full Text] [Related]
4. Specific downregulation of bcl-2 and xIAP by RNAi enhances the effects of chemotherapeutic agents in MCF-7 human breast cancer cells.
Lima RT; Martins LM; Guimarães JE; Sambade C; Vasconcelos MH
Cancer Gene Ther; 2004 May; 11(5):309-16. PubMed ID: 15031723
[TBL] [Abstract][Full Text] [Related]
5. miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.
Zhu W; Xu H; Zhu D; Zhi H; Wang T; Wang J; Jiang B; Shu Y; Liu P
Cancer Chemother Pharmacol; 2012 Mar; 69(3):723-31. PubMed ID: 21993663
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of miR-130a contributes to cisplatin resistance in ovarian cancer cells by targeting X-linked inhibitor of apoptosis (XIAP) directly.
Zhang X; Huang L; Zhao Y; Tan W
Acta Biochim Biophys Sin (Shanghai); 2013 Dec; 45(12):995-1001. PubMed ID: 24145606
[TBL] [Abstract][Full Text] [Related]
7. Inhibiting XIAP expression by RNAi to inhibit proliferation and enhance radiosensitivity in laryngeal cancer cell line.
Wang R; Li B; Wang X; Lin F; Gao P; Cheng SY; Zhang HZ
Auris Nasus Larynx; 2009 Jun; 36(3):332-9. PubMed ID: 19013033
[TBL] [Abstract][Full Text] [Related]
8. Galiellalactone is a novel therapeutic candidate against hormone-refractory prostate cancer expressing activated Stat3.
Hellsten R; Johansson M; Dahlman A; Dizeyi N; Sterner O; Bjartell A
Prostate; 2008 Feb; 68(3):269-80. PubMed ID: 18163422
[TBL] [Abstract][Full Text] [Related]
9. Regulation of HtrA2/Omi by X-linked inhibitor of apoptosis protein in chemoresistance in human ovarian cancer cells.
Yang X; Xing H; Gao Q; Chen G; Lu Y; Wang S; Ma D
Gynecol Oncol; 2005 May; 97(2):413-21. PubMed ID: 15863139
[TBL] [Abstract][Full Text] [Related]
10. Role of XIAP in inhibiting cisplatin-induced caspase activation in non-small cell lung cancer cells: a small molecule Smac mimic sensitizes for chemotherapy-induced apoptosis by enhancing caspase-3 activation.
Checinska A; Hoogeland BS; Rodriguez JA; Giaccone G; Kruyt FA
Exp Cell Res; 2007 Apr; 313(6):1215-24. PubMed ID: 17291493
[TBL] [Abstract][Full Text] [Related]
11. Heterotrimeric stimulatory GTP-binding proteins inhibit cisplatin-induced apoptosis by increasing X-linked inhibitor of apoptosis protein expression in cervical cancer cells.
Cho EA; Oh JM; Kim SY; Kim Y; Juhnn YS
Cancer Sci; 2011 Apr; 102(4):837-44. PubMed ID: 21255191
[TBL] [Abstract][Full Text] [Related]
12. Cisplatin inhibits the expression of X-linked inhibitor of apoptosis protein in human LNCaP cells.
Nomura T; Mimata H; Yamasaki M; Nomura Y
Urol Oncol; 2004; 22(6):453-60. PubMed ID: 15610860
[TBL] [Abstract][Full Text] [Related]
13. Multitarget siRNA inhibition of antiapoptotic genes (XIAP, BCL2, BCL-X(L)) in bladder cancer cells.
Kunze D; Wuttig D; Fuessel S; Kraemer K; Kotzsch M; Meye A; Grimm MO; Hakenberg OW; Wirth MP
Anticancer Res; 2008; 28(4B):2259-63. PubMed ID: 18751404
[TBL] [Abstract][Full Text] [Related]
14. Targeting XIAP bypasses Bcl-2-mediated resistance to TRAIL and cooperates with TRAIL to suppress pancreatic cancer growth in vitro and in vivo.
Vogler M; Walczak H; Stadel D; Haas TL; Genze F; Jovanovic M; Gschwend JE; Simmet T; Debatin KM; Fulda S
Cancer Res; 2008 Oct; 68(19):7956-65. PubMed ID: 18829553
[TBL] [Abstract][Full Text] [Related]
15. Bcl-2 expression as a predictive marker of hormone-refractory prostate cancer treated with taxane-based chemotherapy.
Yoshino T; Shiina H; Urakami S; Kikuno N; Yoneda T; Shigeno K; Igawa M
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6116-24. PubMed ID: 17062688
[TBL] [Abstract][Full Text] [Related]
16. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma.
Ndozangue-Touriguine O; Sebbagh M; Mérino D; Micheau O; Bertoglio J; Bréard J
Oncogene; 2008 Oct; 27(46):6012-22. PubMed ID: 18560353
[TBL] [Abstract][Full Text] [Related]
17. Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells.
Mizutani K; Matsumoto K; Hasegawa N; Deguchi T; Nozawa Y
Exp Oncol; 2006 Sep; 28(3):209-15. PubMed ID: 17080014
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-6 is responsible for drug resistance and anti-apoptotic effects in prostatic cancer cells.
Pu YS; Hour TC; Chuang SE; Cheng AL; Lai MK; Kuo ML
Prostate; 2004 Jul; 60(2):120-9. PubMed ID: 15162378
[TBL] [Abstract][Full Text] [Related]
19. Downregulation of XIAP expression induces apoptosis and enhances chemotherapeutic sensitivity in human gastric cancer cells.
Tong QS; Zheng LD; Wang L; Zeng FQ; Chen FM; Dong JH; Lu GC
Cancer Gene Ther; 2005 May; 12(5):509-14. PubMed ID: 15706355
[TBL] [Abstract][Full Text] [Related]
20. Akt and XIAP regulate the sensitivity of human uterine cancer cells to cisplatin, doxorubicin and taxol.
Gagnon V; Van Themsche C; Turner S; Leblanc V; Asselin E
Apoptosis; 2008 Feb; 13(2):259-71. PubMed ID: 18071906
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
